OnCo
technologiesTechnologyStandard of care

PET tracer manufacturing and distribution

Making PSMA, FDG, and new tracers under drug-manufacturing rules and delivering them daily.

FDA-approved PET drugs are made under cGMP at commercial radiopharmacies (PETNET, Cardinal Health, SOFIE, Jubilant, Curium) or academic sites under ANDA/NDA. New tracers (PSMA agents from Lantheus, Telix, Novartis; FES; FAPI in trials) rely on these networks for launch reach. Kits (Illuccix, Locametz) versus centrally produced doses (Pylarify) is a business-model divide.

Generic schematic · not to scale · placeholder for the imaging front
Detector ring · Tracer uptake · 511 keV photon pair

How it works

Automated radiosynthesis modules, cassette-based chemistry, and rapid QC (radiochemical purity, endotoxin) before release.

Strengths
  • Daily national coverage in the US and Europe
Limitations
  • Tracer approval per site
  • Kit vs central-dose economics
  • Limited reach in low-income countries

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"PET tracer manufacturing and distribution" OR ABSTRACT:"PET tracer manufacturing and distribution") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PET tracer manufacturing and distribution, not a curated reading list.

Connected

13top